SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Epic
Sciences, Inc.'s (Epic) Comprehensive Cancer
Profiling™ Platform continues to deliver compelling cell
analysis information in clinical trials as data being presented
today at the virtual European Society for Medical Oncology Congress
2021 (ESMO 2021) demonstrate.
Data from abstract 577O – "PRINCE: Interim analysis of the phase
Ib study of 177Lu-PSMA-617 in combination with pembrolizumab
for metastatic castration resistant prostate cancer (mCRPC)," being
presented by Shahneen K. Sandhu, MD, principal investigator of
PRINCE and Associate Professor at the Peter MacCallum Cancer
Centre, Victoria, Australia, shows
that the majority of patients' circulating tumor cells (CTCs)
expressing the target Prostate-Specific Membrane Antigen (PSMA) at
baseline were cleared at 12 weeks ,when measured using the Epic
PSMA CTC Assay - prior to other response biomarkers in the
study.
"CTCs provide a non-invasive tool to track drug-target
engagement," said Dr. Sandhu. "This approach could provide
complementary information to PET imaging, so that active treatment
combinations can be identified in other early phase
trials." Biomarker analysis is ongoing in this and other
studies comparing the Epic Sciences PSMA CTC Assay with PSMA and
FDG PET imaging, and patient outcomes.
The capabilities of Epic's Comprehensive Cancer
Profiling™ Platform are also highlighted in two ESMO 2021
posters with leading global collaborators:
Abstract 613P – Chromosomal instability (CIN)
biomarker in circulating tumor cells (CTC) may predict for therapy
resistance in mCRPC.
Abstract 614P – Circulating tumor cell (CTC)
morphologic sub-types present prior to treatment in the CARD trial
identify therapy resistance.
About Epic Sciences
Epic Sciences, Inc. is
developing novel diagnostics to guide therapy selection and monitor
disease progression, personalizing and advancing the treatment and
management of prostate and breast cancer. The company's
Comprehensive Cancer Profiling™ Platform, leverages proven and
proprietary CTC capabilities, and adds ctDNA and immune cell
analysis, to provide more complete data for more efficient analysis
and clearer insights. Epic Sciences partners with leading
pharmaceutical companies and major cancer centers around the world
working to improve patient outcomes.
For more information, visit www.epicsciences.com and follow us
on LinkedIn, Facebook or Twitter.
View original
content:https://www.prnewswire.com/news-releases/epic-sciences-comprehensive-cancer-profiling-platform-shows-compelling-value-of-cell-analysis-in-data-presented-at-esmo-congress-2021-301379904.html
SOURCE Epic Sciences